Progress depends on YOU!
The FDA approval of obeticholic acid (OCA, trade name Ocaliva) for the treatment of PBC represents the first advance since the approval of ursodeoxycholic acid in 1997.
However, several important issues need more study. Your voluntary participation in current and upcoming clinical trials for PBC is crucial for researchers to accelerate progress toward therapies that will benefit each and every individual.
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (Arizona, Florida, Michigan, Texas, Washington & Other Countries)
Recruiting PBC Studies